with leading therapies
This company has developed leading anti-infective therapies, one of which has achieved completely successful Phase 1 (safety) and Phase 2a (dosing) clinical trial results. The company has just completed an interim funding until major funding is secured from VCs and/or licensors.The bridging funds are needed partly to enable the company to continue advancing its drug development and partly to give it sufficient working capital to secure one or more licence deals and to enable it to carry out a Phase 2b trial in the US.
Terms for the present interim funding round are attractive when set against estimates of the company’s valuation.
Click here for full details and update (available for Members of Aurora Private Equity only).